A Call for Innovative Translational and Clinical Research to Address China's Unique Cancer Landscape

The Chinese government has, in recent decades, implemented various administrative laws and regulatory policies to expedite cancer therapeutic development, boosting research and development pipelines for domestic pharmaceutical companies and clinical trials; however, China faces unique challenges giv...

Full description

Saved in:
Bibliographic Details
Published inCancer discovery Vol. 14; no. 11; pp. 2028 - 2032
Main Authors Zhang, Chaoqi, Wu, Peng, Li, Dongyu, Gu, Xuanyu, Lin, Chuqi, Zhou, Junhan, Shang, Dexin, Liu, Jingjing, Ma, Ruijie, Zhao, Bohui, Sun, Nan, He, Jie
Format Journal Article
LanguageEnglish
Published United States 01.11.2024
Subjects
Biomedical Research
China - epidemiology
Humans
Neoplasms - drug therapy
Neoplasms - therapy
Translational Research, Biomedical
China
Online AccessGet full text

Cover

More Information
Summary:The Chinese government has, in recent decades, implemented various administrative laws and regulatory policies to expedite cancer therapeutic development, boosting research and development pipelines for domestic pharmaceutical companies and clinical trials; however, China faces unique challenges given the high prevalence of certain cancer types and distinct disease burdens, some of which are frequently overlooked by international pharmaceutical companies. Given the substantial unmet need for China-specific cancer care, it is crucial to promote the development of innovative pharmaceutical and clinical research in China, with a particular emphasis on addressing tumors most prevalent in its population.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2159-8274
2159-8290
2159-8290
DOI:10.1158/2159-8290.CD-24-0838